Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 2
2001 2
2002 1
2003 1
2004 4
2005 14
2006 17
2007 18
2008 12
2009 12
2010 11
2011 7
2012 8
2013 2
2014 2
2015 2
2016 3
2017 2
2018 1
2021 1
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

106 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With Symptomatic COVID-19: A Randomized Clinical Trial.
Clemency BM, Varughese R, Gonzalez-Rojas Y, Morse CG, Phipatanakul W, Koster DJ, Blaiss MS. Clemency BM, et al. JAMA Intern Med. 2022 Jan 1;182(1):42-49. doi: 10.1001/jamainternmed.2021.6759. JAMA Intern Med. 2022. PMID: 34807241 Clinical Trial.
INTERVENTIONS: Participants were randomly assigned to receive ciclesonide MDI, 160 mug per actuation, for a total of 2 actuations twice a day (total daily dose, 640 mug) or placebo for 30 days. ...The median time to alleviation of all COVID-19-related symptoms was 19.0 day …
INTERVENTIONS: Participants were randomly assigned to receive ciclesonide MDI, 160 mug per actuation, for a total of 2 actuations twi …
Ciclesonide.
Reynolds NA, Scott LJ. Reynolds NA, et al. Drugs. 2004;64(5):511-9; discussion 520-1. doi: 10.2165/00003495-200464050-00005. Drugs. 2004. PMID: 14977388 Clinical Trial.
Inhaled ciclesonide was generally well tolerated in patients with asthma. Ciclesonide did not suppress biochemical markers of adrenal function in 52-week studies. The long-term (>52 weeks) systemic effects of ciclesonide remain unknown....
Inhaled ciclesonide was generally well tolerated in patients with asthma. Ciclesonide did not suppress biochemical markers of …
Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial.
Ezer N, Belga S, Daneman N, Chan A, Smith BM, Daniels SA, Moran K, Besson C, Smyth LY, Bartlett SJ, Benedetti A, Martin JG, Lee TC, McDonald EG. Ezer N, et al. BMJ. 2021 Nov 2;375:e068060. doi: 10.1136/bmj-2021-068060. BMJ. 2021. PMID: 34728476 Free PMC article. Clinical Trial.
OBJECTIVE: To determine if inhaled and intranasal ciclesonide are superior to placebo at decreasing respiratory symptoms in adult outpatients with covid-19. ...INTERVENTION: Participants were randomised to receive either inhaled ciclesonide (600 mug twice daily) and …
OBJECTIVE: To determine if inhaled and intranasal ciclesonide are superior to placebo at decreasing respiratory symptoms in adult out …
Pharmacokinetics of ciclesonide and desisobutyryl ciclesonide after administration via aqueous nasal spray or hydrofluoroalkane nasal aerosol compared with orally inhaled ciclesonide: an open-label, single-dose, three-period crossover study in healthy volunteers.
Nave R, Herzog R, Laurent A, Wingertzahn MA. Nave R, et al. Clin Ther. 2009 Dec;31(12):2988-99. doi: 10.1016/j.clinthera.2009.12.002. Clin Ther. 2009. PMID: 20110036 Clinical Trial.
BACKGROUND: Ciclesonide, an intranasal corticosteroid, is administered as a prodrug and is converted to the active metabolite, desisobutyryl ciclesonide, in the upper and lower airways. ...OBJECTIVE: This study compared the systemic exposure of ciclesonide an …
BACKGROUND: Ciclesonide, an intranasal corticosteroid, is administered as a prodrug and is converted to the active metabolite, desiso …
Deposition and metabolism of inhaled ciclesonide in the human lung.
Nave R, Watz H, Hoffmann H, Boss H, Magnussen H. Nave R, et al. Eur Respir J. 2010 Nov;36(5):1113-9. doi: 10.1183/09031936.00172309. Epub 2010 Mar 29. Eur Respir J. 2010. PMID: 20351025 Free article. Clinical Trial.
Ciclesonide is an inhaled corticosteroid, administered as a prodrug via a metered-dose inhaler. Following deposition in the lung, ciclesonide is hydrolysed by esterases to form the pharmacologically active metabolite desisobutyryl-ciclesonide (des-CIC). ...
Ciclesonide is an inhaled corticosteroid, administered as a prodrug via a metered-dose inhaler. Following deposition in the lung,
Efficacy and safety of ciclesonide nasal spray for the treatment of seasonal allergic rhinitis.
Ratner PH, Wingertzahn MA, van Bavel JH, Hampel F, Darken PF, Shah T. Ratner PH, et al. J Allergy Clin Immunol. 2006 Nov;118(5):1142-8. doi: 10.1016/j.jaci.2006.07.050. Epub 2006 Sep 25. J Allergy Clin Immunol. 2006. PMID: 17088141 Clinical Trial.

Improvements were also noted over days 1 to 28 (P < .001) and over days 15 to 28 (P = .011). Ciclesonide was well tolerated. CONCLUSION: Intranasal ciclesonide was superior to placebo in relieving nasal symptoms in adult and adolescent patients with SAR. These re

Improvements were also noted over days 1 to 28 (P < .001) and over days 15 to 28 (P = .011). Ciclesonide was well tolerated. CONCL

New insights into treatment of children with exercise-induced asthma symptoms.
Stelmach I, Sztafiska A, Jerzyska J, Podlecka D, Majak P, Stelmach W. Stelmach I, et al. Allergy Asthma Proc. 2016 Nov;37(6):466-474. doi: 10.2500/aap.2016.37.3993. Allergy Asthma Proc. 2016. PMID: 27931302 Clinical Trial.
METHODS: Eighty adolescents, ages 1218 years, with asthma and postexercise symptoms were enrolled. Children were treated in one of four treatment groups: ciclesonide 160 microgram daily dose (cic 160), ciclesonide 320 microgram daily dose (cic 320), ciclesonide
METHODS: Eighty adolescents, ages 1218 years, with asthma and postexercise symptoms were enrolled. Children were treated in one of four trea …
Effectiveness of ciclesonide nasal spray in the treatment of seasonal allergic rhinitis.
Ratner PH, Wingertzahn MA, van Bavel JH, Hampel F, Darken PF, Hellbardt S, Brookman S, Shah T. Ratner PH, et al. Ann Allergy Asthma Immunol. 2006 Nov;97(5):657-63. doi: 10.1016/S1081-1206(10)61097-6. Ann Allergy Asthma Immunol. 2006. PMID: 17165276 Clinical Trial.
BACKGROUND: Ciclesonide is an investigational corticosteroid under development for treatment of allergic rhinitis. Ciclesonide is converted to active metabolite, desisobutyryl-ciclesonide (des-CIC), by upper and lower airway esterases. ...
BACKGROUND: Ciclesonide is an investigational corticosteroid under development for treatment of allergic rhinitis. Ciclesonide
Difference between patient-reported side effects of ciclesonide versus fluticasone propionate.
van der Molen T, Foster JM, Caeser M, Müller T, Postma DS. van der Molen T, et al. Respir Med. 2010 Dec;104(12):1825-33. doi: 10.1016/j.rmed.2010.05.021. Epub 2010 Jul 2. Respir Med. 2010. PMID: 20584595 Free article. Clinical Trial.
OBJECTIVES: To compare patient-reported side effects between the inhaled corticosteroids ciclesonide and fluticasone propionate. METHODS: Patients with moderate or moderate-to-severe asthma, pre-treated with a constant dose and type of medication, were randomized in three …
OBJECTIVES: To compare patient-reported side effects between the inhaled corticosteroids ciclesonide and fluticasone propionate. METH …
Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma.
Pedersen S, Engelstätter R, Weber HJ, Hirsch S, Barkai L, Emeryk A, Weber H, Vermeulen J. Pedersen S, et al. Pulm Pharmacol Ther. 2009 Jun;22(3):214-20. doi: 10.1016/j.pupt.2008.12.013. Epub 2008 Dec 27. Pulm Pharmacol Ther. 2009. PMID: 19141327 Clinical Trial.
BACKGROUND: Ciclesonide is a new inhaled corticosteroid (ICS). Information about its clinical efficacy and safety in relation to other ICS in children is needed for clinical positioning. ...Urine free cortisol levels decreased significantly with fluticasone propionate (p=0 …
BACKGROUND: Ciclesonide is a new inhaled corticosteroid (ICS). Information about its clinical efficacy and safety in relation to othe …
106 results